Loading organizations...
Kern Capital is a private equity firm based in Larkspur, California, that invests in a diversified portfolio of new ventures and established businesses across various sectors, with a particular focus on life sciences. The firm typically deploys $5-15 million per deal into a few companies annually, providing capital and strategic advice to outstanding management teams while serving on boards but not engaging in daily operations. Its investment strategy spans diversified sectors including technology-enabled services, cellular communications infrastructure, and niche manufacturing, partnering with management teams of early-stage and growth companies. Kern Capital is funded by high net worth individuals, family offices, and foundations, earning returns through long-term equity investments in its portfolio companies. The firm was founded in early 2020 by Jay Kern, succeeding his prior firm, Kern Whelan Capital.
Kern Capital has 6 tracked investments across 6 companies. The latest tracked deal is $12.0M Other Equity in GPN Vaccines in June 2024.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 5, 2024 | GPN Vaccines | $12.0M Other Equity | Forepont Capital Partners, Kern Capital | — |
| Feb 1, 2021 | Personal Genome Diagnostics | $100.0M Series C | Kevin Raidy | Northpond Ventures, Questa Capital, Vensana Capital, Catalio Capital, Innovatus Capital Partners, NEW Enterprise Associates, PFM Health Sciences, Rock Springs Capital, Sands Capital, Windham Venture Partners |
| May 21, 2019 | Concentric Analgesics | $76.0M Series B | Larry Feinberg | Cowen Healthcare Investments, Venrock |
| Oct 1, 2015 | Quri | $17.0M Series C | Kern Capital | Benchmark, Matrix, Glenn Solomon, Propeller VC, Redpoint Ventures, Catamount Ventures, Matrix Partners, Simon Equity Partners |
| Sep 6, 2012 | UserTesting | $3.0M Other Equity | Kern Capital | — |
| Dec 19, 2011 | Cohera Medical | $25.0M Series C | — | — |
